Research programme: Pak inhibitors - NexGenix
Alternative Names: NX105; NX201; Research programme: neurofibromatosis therapies - NexGenixLatest Information Update: 16 Jul 2016
At a glance
- Originator NexGenix Pharmaceuticals
- Developer NexGenix Pharmaceuticals; Stanford University
- Class Antineoplastics
- Mechanism of Action P21 activated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Fragile X syndrome; Neurofibromatosis 1; Neurofibromatosis 2
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Fragile-X-syndrome in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurofibromatosis 1 and Neurofibromatosis 2 in USA
- 14 Sep 2009 Preclinical trials in Fragile X syndrome in USA (unspecified route)